George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
What's frustrating is the market hammered us when SO returned the licence and then again when the trial did not take place in the UK.
Now we have a trial well under way in Aus and now a new partner for 737, so surely our SP should at least be back to where it was before it collapsed
I see this as a massive green light that all is going well in Aus. We are sitting patiently waiting for news. They however have agreed to invest £5m. Strikes me they know a whole lot more than we do. The start of good news flow is on the way hopefully. Gla
Dear Caroline,
Thankyou for your correspondence of 21 March on behalf of constituent Mr Colin Rogers, about the medicines and Healthcare products Regulatory Agency (MHRA). Please accept my sincere apologies for the delay in replying
I appreciate Mr Rogers concerns
I understand from the MHRA that it did not delay approval of Sareum's clinical trial, but that it rejected the application. For reasons confidentiality, the MHRA is unable to provide details of the clinical trial authorisation (CTA) application to anyone other than the applicant. However, I can confirm that the MHRA's letter of 9 November clearly set out the reasons for the rejection.
Before rejecting a CTA application, the MHRA issues "grounds for no-acceptance (GNA), requesting the applicant provide further information support the trials authorisation. In the GNA letter, the MHRA provides contact details should the sponsor wish too seek further clarification on any GNA point raised
The MHRA recognises that companies need certainty about when their regulatory applications are going to be determined and will provide specific information to each applicant about when they can expect a regulatory decision on their current applications
The MHRA is aware that customers who have submitted initial applications and amendments to its clinical investigations and trials team have experience delays in some cases, and it understands how this unpredictability is affecting companies. To help improve the predicability of decision making for clinical trials, the MHRA has implemented several actions.These include staffing levels returning to normal, staff training, and introducing new processes to reduce the backlogs so that it makes regulatory decisions accordance with statutory timeframes for all new fully compliant clinical trial applications received from 1 September 2023.
The MHRA is also committed to being transparent about its performance in reaching regulatory decisions on each type of fully compliant application. It will publish this data on its website within 15 days after the end of each month ay, www.gov.uk/goverment/publications/mhra-performance-data-for-assesment-of-clinicl-trials-and-established-medicines.
I hope this is helpful
Signed, Will Quince , MP Minister of State
Libarhen,
So sorry to hear the confirmation of Thoths passing, sincere condolences to you and your family.
Without his knowledge and enthusiasm I would not be here today, and he has been very sadly missed by a great deal of people on this board
Wishing you all the best for the future
I have had a response today from my MP, be interesting to see how she gets on!!
Dear Colin
Thank you for your email and I met a company last week who were expressing exactly this concern about the MHRA. However they were talking about 9 month delays, more than twice as long as you have indicated. And of course failure to provide even the information required to companies results in investment and research simply not happening here.
I am more than happy to raise this with Will Quince who is the responsible Minister, if you can let me have some further details, including your full address?
Many thanks
Caroline
Rt Hon Caroline Nokes MP
Member of Parliament for Romsey and Southampton North
Chair of the Women and Equalities Select Committee
Hi all, Interesting I have noticed that since last weeks AGM Peel Hunt have been in the highest buy/sell bracket on level 2, where as before they were often the cheapest. Maybe they have had a talking to!
Merry Christmas everyone, here’s to a better 2023